Komplettering: Hamlet Pharma AB: Hamlet Pharma Interim report Q1; July–September 2021
Nu med text inlagd i meddelandet. Opening remarks During the first quarter of the new fiscal year, Hamlet Pharma secured continued funding, by completing a round of financing with preferential rights for the company’s shareholders. The rights issue was significantly oversubscribed, reflecting investor confidence and a commitment from the shareholders to help secure continued growth of the company. Furthermore, the majority owner Linnane Pharma, demonstrated confidence in Hamlet Pharma by investing approximately 25.3 million SEK to match its share of the Rights Issue. The issue